Janux Therapeutics

Janux is developing next-generation therapeutics based on its proprietary TRACTr platform technology to better treat cancer.

[Janux Therapeutics @januxrx]

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Read the release here: https://t.co/SkYLDKirmI

$JANX

[Janux Therapeutics @januxrx]

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

Read the press release for more: https://t.co/VZR8usVbn9

$JANX

[Janux Therapeutics @januxrx]

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

https://t.co/dpCTHqTbVi

$JANX #TCellEngagers

[Janux Therapeutics @januxrx]

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Read the release here: https://t.co/uPm2D2suss

$JANX #TCellEngagers #cancer #oncology #autoimmunedisease

[Janux Therapeutics @januxrx]

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

Read the press release for more: https://t.co/1nRgCGdO37

$JANX

[Janux Therapeutics @januxrx]

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

Read the release here: https://t.co/330q7d91Av

$JANX

[Janux Therapeutics @januxrx]

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

https://t.co/3RZo9IrwM2

$JANX #TCellEngagers #cancer #oncology

[Janux Therapeutics @januxrx]

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

Read the release for more: https://t.co/HL1zvjeqtS

$JANX

[Janux Therapeutics @januxrx]

Today we announced positive updated interim data from the ongoing Phase 1 trial of JANX007 in #mCRPC that support continued advancement of this PSMA-directed TRACTr.

Join our virtual investor event today at 4:30 pm ET.

Read the release for more: https://t.co/R5mSKZqjKw

$JANX

[Janux Therapeutics @januxrx]

We’ll be hosting a virtual event and live analyst Q&A session on Monday, December 1 at 4:30pm ET to discuss updated Phase 1a and Phase 1b clinical data for JANX007 in #mCRPC.

Read the release for more: https://t.co/XewF4LE42L

$JANX

[Janux Therapeutics @januxrx]

Janux receives 2025 Deloitte Technology #Fast500 recognition. With two drug candidates in clinical trials and more on the way, our progress comes from our great team that works with integrity, collaboration, urgency and commitment.

https://t.co/KhBod4TfdO

[Janux Therapeutics @januxrx]

Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Read the release here: https://t.co/GrpFL0s0OC

$JANX #TCellEngagers #cancer #oncology #autoimmunedisease

[Janux Therapeutics @januxrx]

Thank you @ZEROCancer and #TeamJanux for making the San Diego ZERO Prostate Cancer Run/Walk success and a meaningful way to close #ProstateCancerAwareness Month. Together, we’re moving forward in the community and the clinic toward a future with #ZEROProstateCancer.

#PCAM

[Janux Therapeutics @januxrx]

Our CEO David Campbell joined Josh Schimmer for a fireside chat at the Cantor Global Healthcare Conference 2025, sharing updates on our TRACTr platform, JANX007, and nextgen #TCellEngagers in #oncology and #autoimmunedisease. Listen here: https://t.co/iwT8fTg96G

$JANX #CantorHCC

[Janux Therapeutics @januxrx]

Janux is now 100 strong! United in our mission to deliver precision-engineered immunotherapies, we’re growing with integrity, collaboration & care — pushing science forward while building a culture where people thrive.

#TeamJanux #GoJanux

[Janux Therapeutics @januxrx]

Knowing when to start prostate cancer #screening depends on your risk factors and family history. This #ProstateCancerAwareness Month, learn what’s right for you.

https://t.co/JY9da10PUW

#prostatecancer #PCAM @PCFnews

[Janux Therapeutics @januxrx]

Thank you @Curebound_OFCL and #TeamJanux for a great #cureboundcancerchallenge. 🚴🏽‍♀️🏃🏽‍♀️We're proud to support this event, as we work each day to make a difference in the fight against #cancer.

#GoJanux

[Janux Therapeutics @januxrx]

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Read the release here: https://t.co/a4npQeF7y6

$JANX #TCellEngagers #cancer #oncology

[Janux Therapeutics @januxrx]

Janux announced today that it has achieved a clinical milestone with the dosing of the first patient in a clinical trial under the TRACTr collaboration with Merck.

Read the release for more: https://t.co/KuUk2UVG6A

$JANX

[Janux Therapeutics @januxrx]

#TeamJanux has been hitting the pavement, the gym, and the trails again this year to prepare for this weekend's #cureboundcancerchallenge. 🚴🏽‍♀️🏃🏽‍♀️🏋🏻‍♂️

Learn more about this @Curebound_OFCL event to support life-saving research for patients affected by #cancer: https://t.co/ZdwGixr7JE